Floatz logo

GTI 2040

Metastatic Neoplasm

Aptose Biosciences Inc.nucleic_acidPhase 1/2Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Eloxatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

GTI 2040 is also rated in:

cancer of unknown primary siteDormant
B
Indicative ·
63 / 100
View asset →
male breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →